BD Scores FDA Clearance For Artificial Intelligence Software To Interpret Bacterial Growth

Comments
Loading...
  • The FDA has granted 510(k) clearance to Becton, Dickinson And Company's BDX BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application.
  • Staphylococcus aureus is a bacteria that causes various clinical diseases with potentially serious infections. BD Kiestra uses artificial intelligence software to interpret bacterial growth and release negative specimens. 
  • The imaging application automatically organizes specimens in meaningful worklists with minimal human interaction, enhancing microbiology laboratory efficiency and workflow.
  • Also Read: Becton, Dickinson Shares Dip Despite Q2 Earnings Beat - Here Are The Details
  • The FDA nod will enable medical laboratory scientists and technicians to spend more time on higher-value analysis, reducing the administrative burden on technicians. 
  • The application can evaluate single specimens or group together a large volume of plates.
  • "The pandemic created significant and ongoing labor challenges in laboratories, and reading plates is a labor-intense, potentially error-prone process in microbiology," said Nikos Pavlidis, vice president and general manager for Diagnostics at BD.
  • Price Action: BDX shares are up by 0.17% to $251.50 in premarket on the last check Tuesday.
  • Photo Via Company
Overview Rating:
Speculative
50%
Technicals Analysis
66
0100
Financials Analysis
40
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!